Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Scientists hunt for immune cells that could lead to new MPN therapies

NCT ID NCT07590986

Knowledge-focused Sponsor: Université Catholique de Louvain Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how the immune system reacts to myeloproliferative neoplasms (MPN), a group of blood cancers. Researchers will collect blood and bone marrow samples from 150 adults with or without MPN to find special immune cells (T cells) that recognize and attack MPN cells. The goal is to identify targets and receptors that could be used to design future immune-based treatments. Participants will not receive direct medical benefit, but their samples will help advance MPN research.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 150 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

May 2026

An estimate. Start dates often move.

Expected to finish

Jan 2037

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

(i) Adult patients previously diagnosed with or suspected of having PV, ET, pre-PMF, overt PMF, or an unclassifiable MPN. (ii) Healthy controls undergoing hip replacement surgery, that have not been diagnosed with any hematological disease.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients previously diagnosed or suspected of having PV, ET, pre-PMF, overt PMF, or an unclassifiable MPN. * Patients not previously diagnosed with a haematological disease as controls Exclusion Criteria: * Patients with any other hematological malignancy.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Essential thrombocythemia (ET) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acquired polycythemia vera cellular phase chronic idiopathic myelofibrosis essential thrombocythemia Myeloproliferative Disorders myeloproliferative neoplasm myeloproliferative neoplasm, unclassifiable primary myelofibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Essential thrombocythemia (ET) Myeloproliferative neoplasm (MPN) Polycytemia vera Primary myelofibrosis (PMF)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • de Duve Institute, UCLouvain

    RECRUITING

    Brussels, Woluwe, 1200, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.